23andMe's genome test launches in UK after US ban
This article was originally published in Scrip
23andMe, a genetic testing firm which entered a partnership in September with Pfizer to push the idea of personalized medicines (scripintelligence.com, 1 September 2014), has launched its Personal Genome Service in the UK – a program that has been banned in the US.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.